If your DME program stops at off-the-shelf bracing, you're leaving both patient value and revenue on the table. This session is about what comes next.
Orthopedic DME has evolved well past standard bracing. Biologics, cold therapy, and other emerging offerings are reshaping what a complete program looks like. Alek Johnson shares what's worked, and what hasn't, in expanding his own multi-site portfolio, including how to evaluate new product and service lines for operational fit, reimbursement viability, and impact on the post-operative patient experience.
Then it's your turn at the table. In the open roundtable, bring the offerings you're considering and get direct, practitioner-level feedback before you commit resources to them.
Learning Objectives
This series is made possible with the support of Select Ortho.
Alek Johnson is Director of Cast Room & Durable Medical Equipment at Midwest Orthopaedics at Rush, based in Chicago, IL, where he leads multi-site DME operations across 7 clinic locations and 12 ASCs. He oversees programs including bracing, biologics, cold therapy, and injection workflows, with a focus on scalable growth, compliance, and patient experience. Alek has driven significant revenue expansion through standardized workflows and strategic vendor partnerships. He serves as a Senior Advisor within the Academic Orthopaedic Consortium (AOC) DME Leadership Group and collaborates with peers and industry partners to advance national best practices in DME.